停用脂质体布比卡因对初次全膝关节置换术后疼痛管理无影响
该研究比较了全膝关节置换术中停用脂质体布比卡因(LB)前后两组患者,发现停用LB在术后72小时疼痛评分、96小时阿片类药物用量及24小时功能评分上均无显著差异,结论是多模式镇痛方案中加入LB并未改善镇痛效果。
要点
- 停用LB后术后72小时VRS疼痛评分无显著差异(p>0.05)。
- 停用LB后术后96小时阿片类药物用量无显著差异(p>0.05)。
- 停用LB后术后24小时AM-PAC功能评分无显著差异(p>0.05)。
核心结论
- 在多模式镇痛方案中,加入脂质体布比卡因相比传统布比卡因并未改善全膝关节置换术后的疼痛控制。
研究设计与样本
- 回顾性对比研究,比较2019年7月1日停用LB前连续888例接受Protocol 1(含LB)的患者与停用后连续789例接受Protocol 2(不含LB)的患者,所有患者均接受相同的阿片类药物节约方案。
主要发现
- 停用LB组平均年龄显著高于LB组(66.80 vs 65.57岁,p=0.006),两组性别、BMI、ASA评分、种族、吸烟状态、婚姻状态、手术时间、住院时长及出院去向相似。
- 停用LB组与LB组相比,术后72小时内VRS疼痛评分无显著差异(p>0.05)。
- 停用LB组与LB组相比,术后96小时内阿片类药物给药无显著差异(p>0.05)。
- 停用LB组与LB组相比,术后24小时内AM-PAC评分无显著差异(p>0.05)。
临床怎么用
- 在全膝关节置换术的多模式镇痛方案中,可考虑停用脂质体布比卡因,因其未显示额外获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Liposomal bupivacaine (LB) as part of a periarticular injection protocol continues to be a highly debated topic in total knee arthroplasty (TKA). We evaluated the effect of discontinuing the use of LB in a periarticular protocol on immediate postoperative pain scores, opioid consumption, and objective functional outcomes. METHODS: On 1 July 2019, we discontinued the use of intraoperative LB as part of a periarticular injection protocol. A consecutive group of patients who received LB as part of the protocol (Protocol 1) and a subsequent group who did not (Protocol 2) were compared. All patients received the same opioid-sparing protocol. Verbal rating scale (VRS) pain scores were collected from our electronic data warehouse and averaged per patient per 12-hour interval. Events relating to the opiate administration were derived as morphine milligram equivalences (MMEs) per patient per 24-hour interval. The Activity Measure for Post-Acute Care (AM-PAC) tool was used to assess the immediate postoperative function. RESULTS: A total of 888 patients received Protocol 1 and while 789 received Protocol 2. The mean age of the patients was significantly higher in those who did not receive LB (66.80 vs 65.57 years, p = 0.006). The sex, BMI, American Society of Anesthesiologists physical status score, race, smoking status, marital status, operating time, length of stay, and discharge disposition were similar in the two groups. Compared with the LB group, discontinuing LB showed no significant difference in postoperative VRS pain scores up to 72 hours (p > 0.05), opioid administration up to 96 hours (p > 0.05), or AM-PAC scores within the first 24 hours (p > 0.05). CONCLUSION: The control of pain after TKA with a multimodal management protocol is not improved by the addition of LB compared with traditional bupivacaine. Cite this article: Bone Joint J 2021;103-B(6 Supple A):102-107.
引用
- Feng JE, Ikwuazom CP, Mahure SA, et al. Discontinuation of the liposomal delivery of bupivacaine has no effect on pain management after primary total knee arthroplasty : no effect on pain scores, opioid consumption, or functional status. Bone Joint J. 2021. PMID: 34053282. doi:10.1302/0301-620X.103B6.BJJ-2020-2033.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。